Interleukin-18 promotes the antitumor ability of natural killer cells in colorectal cancer via the miR-574-3p/TGF-β1 axis

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Society AC. Cancer facts & figures 2019. Atlanta: American Cancer Society; 2019.
   Google Scholar
• Le DT, Hubbard-Lucey VM, Morse MA, et al. A blueprint to advance colorectal cancer immunotherapies. Cancer Immunol Res. 2017;5(11):942–949.
   PubMed Web of Science ®Google Scholar
• Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3(4):3856–3893.
   PubMedGoogle Scholar
• Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003;73(2):213–224.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Novick D, Kim S, et al. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4:289.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507.
   PubMed Web of Science ®Google Scholar
• Park IH, Yang HN, Lee KJ, et al. Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer. Oncotarget. 2017;8(20):32722–32730.
   PubMedGoogle Scholar
• Timperi E, Focaccetti C, Gallerano D, et al. IL-18 receptor marks functional CD8(+) T cells in non-small cell lung cancer. Oncoimmunology. 2017;6(7):e1328337.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kassem S, Cleynen A, et al. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. 2018;33(4):634–648.e635.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Hazama S, Iizuka N, et al. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence. Cancer Gene Ther. 2001;8(1):9–16.
   PubMed Web of Science ®Google Scholar
• Gatault S, Delbeke M, Driss V, et al. IL-18 is involved in eosinophil-mediated tumoricidal activity against a colon carcinoma cell line by upregulating LFA-1 and ICAM-1. J Immunol. 2015;195(5):2483–2492.
   PubMed Web of Science ®Google Scholar
• Muthusami S, Ramachandran I, Krishnamoorthy S, et al. Regulation of microRNAs in inflammation-associated colorectal cancer: a mechanistic approach. Endocr Metab Immune Disord Drug Targets. 2020;21(1):67–76.
   Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Shirjang S, et al. Micro-RNAs: the new potential biomarkers in cancer diagnosis, prognosis and cancer therapy. Cell Mol Biol (Noisy-le-grand). 2015;61(5):1–10.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Sandoghchian Shotorbani S, Baradaran B. RNA interference and its role in cancer therapy. Adv Pharm Bull. 2014;4(4):313–321.
   PubMedGoogle Scholar
• Mansoori B, Mohammadi A, Shirjang S, et al. Micro RNA 34a and Let-7a expression in human breast cancers is associated with apoptotic expression genes. Asian Pac J Cancer Prev. 2016;17(4):1887–1890.
   PubMedGoogle Scholar
• Mohammadi A, Mansoori B, Baradaran B. The role of microRNAs in colorectal cancer. Biomed Pharmacother. 2016;84:705–713.
   PubMed Web of Science ®Google Scholar
• Li Q, Huyan T, Cai S, et al. The role of exosomal miR-375-3p: a potential suppressor in bladder cancer via the Wnt/β-catenin pathway. Faseb J. 2020;34(9):12177–12196.
   PubMed Web of Science ®Google Scholar
• Yu S, Lu Z, Liu C, et al. MiRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010;70(14):6015–6025.
   PubMed Web of Science ®Google Scholar
• Christensen LL, Tobiasen H, Holm A, et al. MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer. Int J Cancer. 2013;133(1):67–78.
   PubMed Web of Science ®Google Scholar
• Angius A, Pira G, Scanu AM, et al. MicroRNA-425-5p expression affects BRAF/RAS/MAPK pathways in colorectal cancers. Int J Med Sci. 2019;16(11):1480–1491.
   PubMed Web of Science ®Google Scholar
• Ashraf NM, Imran K, Kastner DW, et al. Potential involvement of mi-RNA 574-3p in progression of prostate cancer: a bioinformatic study. Mol Cell Probes. 2017;36:21–28.
   PubMed Web of Science ®Google Scholar
• Li WC, Wu YQ, Gao B, et al. MiRNA-574-3p inhibits cell progression by directly targeting CCND2 in colorectal cancer. Biosci Rep. 2019;39(12):BSR20190976.
   PubMedGoogle Scholar
• Zhang P, Zhu J, Zheng Y, et al. MiRNA-574-3p inhibits metastasis and chemoresistance of epithelial ovarian cancer (EOC) by negatively regulating epidermal growth factor receptor (EGFR). Am J Transl Res. 2019;11(7):4151–4165.
   PubMed Web of Science ®Google Scholar
• Zhou H, Wang K, Hu Z, et al. TGF-β1 alters microRNA profile in human gastric cancer cells. Chin J Cancer Res. 2013;25(1):102–111.
   PubMed Web of Science ®Google Scholar
• Zhang R, Wang M, Sui P, et al. Upregulation of microRNA-574-3p in a human gastric cancer cell line AGS by TGF-β1. Gene. 2017;605:63–69.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang Y, Ding L, et al. LncRNA MIR4435-2HG inhibits the progression of osteoarthritis through miR-510-3p sponging. Exp Ther Med. 2020;20(2):1693–1701.
   PubMed Web of Science ®Google Scholar
• Chakrabarti M, Ray SK. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. Apoptosis. 2016;21(3):312–328.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Luo M, Lü M, et al. Let-7c-5p inhibits cell proliferation and migration and promotes apoptosis via the CTHRC1/AKT/ERK pathway in esophageal squamous cell carcinoma. Onco Targets Ther. 2020;13:11193–11209.
   PubMed Web of Science ®Google Scholar
• Xu JH, Chen RZ, Liu LY, et al. LncRNA ZEB2-AS1 promotes the proliferation, migration and invasion of esophageal squamous cell carcinoma cell through miR-574-3p/HMGA2 axis. Eur Rev Med Pharmacol Sci. 2020;24(10):5391–5403.
   PubMed Web of Science ®Google Scholar
• Cekaite L, Eide PW, Lind GE, et al. MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget. 2016;7(6):6476–6505.
   PubMedGoogle Scholar
• Mizuno R, Kawada K, Sakai Y. The molecular basis and therapeutic potential of Let-7 microRNAs against colorectal cancer. Can J Gastroenterol Hepatol. 2018;2018:5769591.
   PubMed Web of Science ®Google Scholar
• King CE, Wang L, Winograd R, et al. LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene. 2011;30(40):4185–4193.
   PubMed Web of Science ®Google Scholar
• Xu H, Liu X, Zhou J, et al. MiR-574-3p acts as a tumor promoter in osteosarcoma by targeting SMAD4 signaling pathway. Oncol Lett. 2016;12(6):5247–5253.
   PubMed Web of Science ®Google Scholar